<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a071_form6-k.txt
<TEXT>
                                    FORM 6-K


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                        Report of Foreign Private Issuer
                      Pursuant to Rule 13a-16 or 15d-16 of
                       the Securities Exchange Act of 1934

                                October 27, 2003

                          Commission File No. 000-26498

                             NUR MACROPRINTERS LTD.
             (Exact Name of Registrant as specified in its Charter)

                                 Not Applicable
                 (Translation of Registrant's Name into English)

                          12 Abba Hilel, Silver Street
                                       Lod
                                  71111 Israel
                    (Address and principal executive offices)


Indicate by check mark whether the registrant  files or will file annual reports
under cover Form 20-F or Form 40-F.

                Form 20-F     X         Form 40-F
                           --------                 -------

Indicate by check mark whether the  registrant  by  furnishing  the  information
contained  in this  Form is  also  thereby  furnishing  the  information  to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                      Yes                      No      X
                           --------                 --------

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b).

     Attached hereto and  incorporated by reference herein is a press release of
the registrant dated October 27, 2003.

<PAGE>

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.

                                                       NUR MACROPRINTERS LTD.



Date:    November 2, 2003                              By: /s/ DAVID AMIR
                                                           ---------------------
                                                       David Amir
                                                       Chief Executive Officer

<PAGE>

NUR MACROPRINTERS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS

Expect Operating Profitability and Net Income in Fourth Quarter 2003

Revaluation of Inventory Results in $4.5m Write-Off


  LOD,  Israel;  October 27, 2003 -- NUR  Macroprinters  (Nasdaq-SCM:  NURM),  a
  leading supplier of wide-format  inkjet  production  printing  systems,  today
  announced  its  consolidated  financial  results for the nine months and third
  quarter ended September 30, 2003.

  Revenues for the third  quarter of 2003 were $17.1  million  compared to $20.9
  million in the third quarter of 2002,  where most of the decline is attributed
  to the discontinued substrate product line, and $13.1 million during the prior
  quarter,  where  most of the  increase  is  attributed  to  increase  sales of
  printers.  Taking  into  account a write-off  of  inventory  of $4.5  million,
  operating loss in the third quarter of 2003 was ($4.8) million. Excluding this
  inventory  write-off,  the  operating  loss  declined  to  ($328,000)  from an
  operating  loss of  ($684,000) in the third quarter of last year and a ($1.14)
  million  operating loss in the prior quarter  (excluding  one-time charges and
  restructuring  costs in previous  quarter).  Without such exclusion  operating
  losses were  ($15.4)  million in the second  quarter.  Taking into account the
  above  mentioned  inventory  write-off,  net loss for the  third  quarter  was
  ($5,460,000), or ($0.32) per share. Excluding this write-off, net loss for the
  third quarter was ($948,000),  or ($0.05) per share, compared to a net loss of
  ($1.2)  million,  or ($0.07) per share,  in the third  quarter last year and a
  prior  quarter  loss of ($1.7)  million,  or  ($0.10)  per  share,  (excluding
  one-time costs and write-offs in the previous quarter).Without such exclusions
  net losses in the previous quarter were ($16.0) million.

  Revenues  for the first nine  months of 2003 were $47.3  million,  compared to
  $65.7  million  during  the first nine  months of 2002.  Taking  into  account
  one-time  costs and write-off of inventory  operating  loss for the first nine
  months of 2003 was approximately  ($21.3) million versus ($5.8) million in the
  same period last year. Excluding one-time costs and write-offs, operating loss
  for the first nine  months of 2003 was  approximately  ($2.5)  million  versus
  ($4.9)  million in the same  period last year.  Taking into  account the above
  mentioned  one-time costs and write-offs net loss for the first nine months of
  2003 was ($22.9)  million,  or ($1.33) per share, as compared to a net loss of
  ($7.0)  million,  or ($0.41) per share,  in the  comparable  period last year.
  Excluding  one-time  costs and  write-offs net losses in the first nine months
  2003 and prior  year were $4.1  million,  or  ($0.24)  per  share,  and ($6.1)
  million, or ($0.36) per share, respectively.

  The Company has reported  that during the third  quarter 2003 it had completed
  the previously announced consolidation of its production facilities in Israel,
  which  involved a  revaluation  process of its  inventory.  As a result of the
  completion of the consolidation and in order to better reflect inventory value
  the Company decided on a write-off of inventory of $4,512,000.

<PAGE>

  Based on the third quarter  results,  the Company does not meet certain of the
  financial covenants set forth in its loan agreements. The Company is currently
  in the process of  obtaining  a waiver from the banks for the  above-mentioned
  non-compliance.  Based on preliminary  discussions with the banks, the Company
  believes that such waiver will be granted.  Should the waiver not be obtained,
  the Company's  long-term debt of $30.7 million shall be  reclassified as short
  term  debt,  resulting  in a short  term  debt  of  $42.6  million  and not as
  presented herein.

  David Seligman,  Chief Financial Officer of NUR Macroprinters,  commented, "We
  believe that the results that we are reporting  today,  clearly  indicate that
  NUR is on the right  path to return to growth  and  profitability.  We've been
  successful  in  increasing  the  level of  quality  of our  receivables  while
  lowering our DSOs, as well as reducing our operating expenses.  Going forward,
  we expect to return to  profitability  in the  fourth  quarter  of 2003 and to
  continue to improve our balance sheet and financial performance."

  David Amir,  CEO and President of NUR  Macroprinters,  commented,  "During the
  third quarter we launched two new products - the NUR Tempo(TM) flatbed presses
  and the NUR Ultima(TM) mid-range volume inkjet production printers. The Ultima
  has been well  received  and has  already  been  installed  in several  sites,
  including a U.S. site with two machines..  The Tempo flatbed presses completed
  a  successful  beta  testing  program  and  began  shipping   commercially  in
  September.  Seven units were sold during the third quarter and we anticipate a
  great potential market for this product.  We feel confident of future sales of
  these two new products."

  Amir continued, "As recently announced, we have completed the consolidation of
  all of NUR's equipment  manufacturing  operations in one facility in Israel. A
  second Israel based  facility has become our ink production  center,  where we
  produce  the  inks  for  most of our  printers.  Last  week we  announced  the
  relocation and consolidation of all of our North American  activities to a new
  North American  headquarters  and training  facility,  located in the New York
  metro area.  Following the successful model of NUR Europe,  we have re-aligned
  NUR  America  and  NUR  Asia  Pacific  so  that  each  region  now has a local
  management  team.  This  allows for a stronger  market  presence  and  greater
  customer responsiveness."

  Mr. Amir concluded,  "During the past few quarters, we have made major changes
  in  operations  and  senior  management  designed  to  enhance  our  financial
  controls.  We believe that this,  together  with the  additions to our product
  offering,  will enhance our ability to successfully compete in the wide-format
  digital printing arena."

  The Company will host a conference  call to discuss  these  results on Monday,
  October 27th at 12:00 pm EST. To participate, please call 1-877-356 9548 (U.S.
  toll   free),   1-800-945-7877   (Israel   toll   free)  or  +1-706  679  0587
  (International),  ID Code: "3463428". A PowerPoint  presentation  highlighting
  key financial  metrics will be available in the Investor  Relations section of
  the  Company's web site,  www.nur.com  through the Fourth  Quarter  2003.  The
  conference call also will be available for replay for 14 days starting 2pm EDT
  on the day of the call,  by  calling  1-800 642 1687  (U.S.) / +1-706 645 9291
  (International and Israel) and enter conference ID number "3463428".

<PAGE>

ABOUT NUR MACROPRINTERS LTD.
NUR Macroprinters (Nasdaq-SCM: NURM) is a leading supplier of wide-format inkjet
printing systems used for the production of out-of-home  advertising  materials.
From entry-level photo-realistic printers to high-throughput production presses,
NUR's complete line of cost-effective, reliable printing solutions and companion
inks are helping  customers  in over 100  countries  worldwide  address the full
spectrum  of  wide-format  printing  requirements.   NUR  customers,   including
commercial printing  companies,  sign printers,  screen printers,  billboard and
media companies,  photo labs, and digital printing service  providers,  count on
NUR to help them deliver the high quality and fast  turnaround they need to meet
their clients' exacting demands and succeed in today's competitive  marketplace.
More information about NUR Macroprinters is available at www.nur.com .

                               (TABLES TO FOLLOW)

SAFE  HARBOR:  Certain  statements  made herein  that use the words  "estimate,"
"project," "intend," "expect," "believe" and similar expressions are intended to
identify forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These  forward-looking  statements  involve known
and  unknown  risks and  uncertainties  that  could  cause the  actual  results,
performance or achievements of NUR Macroprinters Ltd. To be materially different
from those  which may be  expressed  or implied by such  statements,  including,
among  others,   changes  in  general  economic  and  business   conditions  and
specifically,  decline in demand for NUR Macroprinters Ltd's products, inability
to timely develop and introduce new technologies,  products and applications and
loss of market  share and pressure on prices  resulting  from  competition.  For
additional  information  regarding  these  and  other  risks  and  uncertainties
associated with the Company's  business,  reference is made to NUR Macroprinters
Ltd.'s  reports  filed  from  time to time  with  the  Securities  and  Exchange
Commission.    This   press   release   is   available   at   www.nur.com    and
www.portfoliopr.com/

                             NUR MACROPRINTERS LTD.
                             ----------------------
                   Condensed Balance Sheets, US$ in thousands

<TABLE>
<CAPTION>


                                              30-Sep-03    31-Dec-02    Change
                                             -----------   ----------  ---------
                                              Unaudited      Audited

<S>                                           <C>           <C>            <C>
Current Assets:
  Cash and cash equivalents                   $    9,292    $  11,668      (21%)
  Accounts receivable - trade                     21,460       28,777      (25%)
  Other receivables and prepaid expenses           6,209        5,531       12%
  Inventories                                     15,907       24,297      (35%)
                                              ----------    ---------    -------

Total Current Assets                              52,868       70,273      (25%)
                                              ----------    ---------    -------

Investments and other non-current assets
----------------------------------------
Long-term accounts receivables - trade               547        1,760      (69%)
Investments and other non-current assets           2,446        2,516       (3%)
Severance pay funds                                  813          916      (11%)
                                              ----------    ---------    -------

                                                   3,806        5,192      (27%)
                                              ----------    ---------    -------

Property and Equipment, net                        8,786       11,576      (24%)

Other assets, net                                    776          854       (9%)
                                              ----------    ---------    -------

Total assets                                       6,236       87,895      (25%)
                                              ==========    =========    =======

Liabilities and Shareholders' Equity
------------------------------------
Current Liabilities:
Short - term1 bank credit                         11,908        5,844      104%
Current maturities of long - term loans              142        2,020      (93%)
Trade payables                                     8,735       16,444      (47%)
Accrued expenses and other liabilities            12,767        8,984       42%
Advances from customers                              501          270       86%
                                              ----------    ---------    -------

<PAGE>

Total Current Liabilities                         34,053       33,562        1%
                                              ----------    ---------    -------
Long -Term Liabilities:
Long - Term loans1                                30,673       30,051         2%
Accrued severance pay                                944        1,122      (16%)
                                              ----------    ---------    -------

                                                  31,617       31,173         1%
                                              ----------    ---------    -------

Shareholders' Equity:
--------------------
Share capital                                      4,244        4,202         1%
Capital surplus                                   45,750       45,697         0%
Cumulative translation adjustment                (1,087)      (1,286)      (15%)
Accumulated Earnings (Deficit)                   48,341)     (25,453)        90%
                                              ----------    ---------    -------

Total Shareholders' Equity                           566      23,160       (98%)
                                              ----------    ---------    -------
Total Liabilities and Shareholders' Equity        66,236      87,895       (25%)
                                              ==========    =========   ========

</TABLE>

----------
1    Based on the third  quarter  results,  the Company does not meet certain of
     the financial  covenants set forth in its long-term  loan  agreements.  The
     Company is  currently  in the process of  obtaining a waiver from the banks
     for the  above-mentioned  non-compliance and believes that such waiver will
     be granted. Should the waiver not be obtained, the Company's long-term debt
     of $30.7 million shall be reclassified  as short term debt,  resulting in a
     short term debt of $42.6 million and not as presented above.

<PAGE>


                             NUR MACROPRINTERS LTD.
                             ----------------------
                      Consolidated Statements Of Operations
                   U.S. $ in thousands, except per share data

<TABLE>
<CAPTION>

                                                            Nine Months ended                            Three Montsh ended
                                                  ---------------------------------------------   ---------------------------------
                                                   9/30/2003   9/30/2003   9/30/2002  9/30/2002   9/30/2003  9/30/2003   9/30/2002
                                                  ----------  -----------  ---------  ---------   ---------  ---------   ----------
                                                     GAAP     Non GAAP(1)    GAAP     Non GAAP(2)   GAAP     Non GAAP(3)    GAAP
                                                  ----------  -----------  ---------  ----------  ---------  -----------  ---------
                                                               Performa               Performa               Performa
                                                   Unaudited   Unaudited   Unaudited  Unaudited   Unaudited  Unaudited   Unaudited
<S>                                               <C>         <C>          <C>        <C>         <C>        <C>         <C>
Revenues
  Sales of printers and related products          $   47,332  $    47,332  $  65,734  $   65,734  $  17,136  $  17,136   $  20,925
                                                  ----------  -----------  ---------  ----------  ---------  ---------   ---------
Cost of revenues
  Cost of sales of printers and related
  products                                            29,204       29,204     45,094      45,094      9,979      9,979      13,357
  inventory write-off                                 10,034            0          0       4,512          0          0           0
                                                  ----------  -----------  ---------  ----------  ---------  ---------   ---------
                                                      39,238       29,204     45,094      45,094     14,194      9,979      13,357
                                                  ----------  -----------  ---------  ----------  ---------  ---------   ---------
Gross profit                                           8,094       18,128     20,640      20,460      2,645      7,157       7,568
                                                       17.10%       38.30      31.40%     31.40%      15.44%     41.77%     36.17%

Research & Development expenses                        5,530        5,530      6,854      6,854       1,696      1,696       2,257
Less-Grants                                             (687)         687)    (1,110)    (1,110)        (89)       (89)      (546)
                                                  -----------  -----------  --------- ----------  --------- ----------  ----------
Research & Development expenses, net                   4,843        4,843      5,744       5,744      1,607      1,711       1,711

Selling expenses, net                                  8,670        8,670      9,437       9,437      2,786      2,786       2,937
General and administrative expenses                    7,142        7,142      8,873       8,873      3,092      3,092       3,101
Amortization of intangible assets                          0            0      1,505       1,505          0          0         503
One time doubtful debts expenses                       6,694            0          0           0          0          0           0
Restructuring and other one time expenses              2,074            0        848           0          0          0           0
                                                  ----------  -----------  ---------  ----------  ---------  ---------   ---------
                                                      24,580       15,812     20,663      19,815      5,878      5,878       6,541
Operating income (loss)                              (21.329)      (2,527)    (5,767)     (4,919)    (4,840)      (328)      (684)
Financial expenses net                                (1,250)      (1,250)      (929)       (929)      (313)      (313)      (473)
Other expense net                                       (103)        (103)      (135)       (135)      (259)      (259)       (27)
                                                  ----------  -----------  ---------  ----------  ---------  ---------   ----------


Loss before taxes on income and equity losses       (22,682)       (3,880)    (6,831)     (5,983)    (5,412)     (900)     (1,184)
Taxes on income                                        (206)         (206)      (127)       (127)       (48)      (48)        (52)
Equity in profits (losses) of affiliates, net
of taxes                                                   0            0          0           0         0          0           0
                                                  ----------  -----------  ---------  ----------  ---------  ---------   ----------

Net loss for the period                           $  (22,888) $    (4,086)    (6,958)     (6,110)  $ (5,460)  $   (948)   $( 1,236)
                                                  ==========  ===========  =========  ==========  =========  =========   ==========
                                                     (48.36%)      (8.63%)   (10.59%)     (9.30%)   (31.86%)   (5.53%)      (5.91%)

Loss per share                                    $    (1.33) $     (0.24) $   (0.41) $    (0.36)  $  (0.32) $  (0.05)   $   (0.07)
                                                  ==========  ===========  =========  ==========  =========  =========   ==========

Loss per share                                    $    (1.33) $     (0.24) $   (0.41) $    (0.36) $   (0.32) $   (0.05)  $   (0.07)
                                                  ==========  ===========  =========  ==========  =========  =========   ==========

Weighted average number of shares

  outstanding during the period                   17,206,280   17,206,280 16,898,965  16,898,965 17,276,506  17,276,506  17,099,010
                                                  ==========  =========== ==========  ========== ==========  ==========  ==========
 Weighted average number of shares outstanding
during the period used for diluted loss per
share                                                     --           --         --          --         --         --         --
                                                  ==========  ===========  =========  ==========  =========  =========   ==========

</TABLE>

Non GAAP Performa results of operations excludes the following expenses: (1)

----------

(1)  Excluding  $2.1 million of  restructuring  expenses and $6.7 million of one
     time  doubtful  debts  expenses and one time  inventory  write-offs of $5.5
     million in the first  quarter  and $4.5  million in the third  quarter
(2)  Excluding restructuring and other one time expenses of $ 0.8 million
(3)  Excluding restructuring and other one time expenses of $ 4,512 thousand

</TEXT>
</DOCUMENT>
